3 stocks primed to outperform

Sometimes the best place to look for companies that will outperform in the future is to look at companies that have a record of outperforming in the past but for one reason or another have underperformed in the recent past.

This style of investing is often described as ‘contrarian’ and it’s not easy! The reason it’s not easy is it goes against human nature to ‘go against the crowd’ and to buy shares of a company when other investors are selling. Contrarian investing requires independent thinking and conviction — 2 traits Warren Buffett has mastered and that many other investors have not.

As the chart below shows, the following three blue-chip stocks have all underperformed the 6% return from the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) over the past six months. While none of these blue chips have announced any ‘life-threatening’ problems, each has ‘small negatives’ hovering over it, which is likely cause of their respective share price underperformances.

In insurer AMP’s (ASX: AMP) case, the 7% decline in its shares is due to a surprise downgrade to earnings in June that preceded its interim results release. The cause of the downgrade was poor claims and lapse experience in its Australian wealth protection business which caught the market off-guard and led to a selloff in the share price. While the share price has regained much of the recent losses it appears the market is taking a more conservative approach to the full year outlook for AMP.

Meanwhile, stock exchange operator ASX (ASX: ASX) has seen its share price nearly flat over the past six months, which is interesting when you consider the growing momentum for corporate activity such as initial public offerings and the market hitting multi-year highs. There isn’t really any ‘bad news’ to pin on the ASX, however a large discounted capital raising and a flat underlying profit are likely the reasons behind the recent relative underperformance of its shares.

Rounding out the three high quality companies whose shares have underperformed the index is implantable hearing device company Cochlear (ASX: COH). Cochlear was forced to downgrade market expectations in the lead up to its full year results due to weaker sales. Some analysts have become concerned that the company faces increased competition from rivals, however with the release of its new Nucleus 6 sound processor suite of products, Cochlear should continue to enjoy a strong growth trajectory.


Source: Google Finance

Foolish takeaway

When a quality company stumbles it can be a great opportunity to purchase stock. The recent ‘stumbles’ at AMP, ASX and Cochlear have each led to their share prices underperforming the market and could offer a good entry point for investors into these blue chip companies that have good long-term prospects.

Many out-of-favour stocks also provide above average dividend yields however we have an even better income idea! Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.